Skip to content

Effects of percutaneous auricular vagus nerve stimulation in chronic widespread myofascial pain syndrome

Effects of percutaneous auricular vagus nerve stimulation in chronic widespread myofascial low back and cervical pain syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20221230056989N1
Enrollment
68
Registered
2023-01-30
Start date
2023-08-23
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Widespread Myofascial Low Back and Cervical Pain Syndrome. Chronic pain syndrome

Interventions

Intervention group: The intervention group is assigned 10 sessions of percutaneous auricular vagus nerve stimulation (biphasic rectangular with 250 microseconds pulse and 25 Hz) is applied for 30 min

Sponsors

University of social welfare and rehabilitation sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 55 Years

Inclusion criteria

Inclusion criteria: Patients in age 25 to 55 years Body mass index less than 30 kg/m2 Having the criteria of lumbar and neck myofascial syndromes based on the criteria provided by Travell and Simon in the muscles of the back and neck the patient have pain for at least 3 months. The presence of at least 3 trigger points in the muscles of the back and neck, where one of these two areas involves the muscles bilaterally (by using an algometer, as well as by touch) Intensity of pain of at least 3 out of 10 on the Visual Analog Scale (VAS) Patients whose Wide Spread Pain Index (WPI) is equal to or greater than 7

Exclusion criteria

Exclusion criteria: Neurological diseases Metabolic and endocrine diseases Systemic diseases such as lupus, scleroderma Infectious diseases Inflammatory diseases Thyroid diseases History of malignancy Diabetes Pregnancy Menopause Use of painkillers in the last 24 hours Long-term use of corticosteroids Drug addiction Cognitive and psychotic diseases Myopathies Cardiovascular diseases Taking drugs that affect the autonomic system, such as cholinergic and anticholinergic drugs, alpha and beta blockers, antipsychotics

Design outcomes

Primary

MeasureTime frame
Heart Rate Variability (HRV). Timepoint: Before and after 10 sessions. Method of measurement: PowerLab data acquisition system.

Secondary

MeasureTime frame
Low Back Pain Disability. Timepoint: Before and after 10 sessions. Method of measurement: Oswestry Low Back Pain Disability (ODI).;Low Back Pain Diability. Timepoint: Before and after 10 sessions. Method of measurement: Roland-Morris Disability Questionnaire (RMQ).;Neck Disability. Timepoint: Before and after 10 sessions. Method of measurement: Neck Disability Index (NDI).;Kinesiophobia. Timepoint: Before and after 10 sessions. Method of measurement: Tampa Scale of Kinesiophobia (TSK).;Anxiety. Timepoint: Before and after 10 sessions. Method of measurement: Beck Anxiety Inventory (BAI).;Heart Rate Variability. Timepoint: Before and after 10 sessions. Method of measurement: PowerLab data acquisition system.;Pain Pressure Threshold (PPT). Timepoint: before and after 10 sessions. Method of measurement: algometer.;Pain. Timepoint: before and after 10 sessions. Method of measurement: Visual Analog Scale (VAS).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahboobeh Abdolalizadeh

University of social welfare and rehabilitation sciences

mahabd55@gmail.com+98 34 3265 3297

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026